<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="at: [[inbox]]
Endocrinology - Diabetes - Fast Facts | NEJM Resident 360 Diabetes is a common condition that is managed in both the inpatient and outpatient settings."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle=Endocrinology - Diabetes - Fast Facts | NEJM Resident 360"><title>Endocrinology - Diabetes - Fast Facts | NEJM Resident 360</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.acd6336f837a791cf1889bb120dfb142.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.4fe30220d181aec51e691c4ef9fc1ea7.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.52473d7683b63bbf2dbd7fa97fd51c78.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Endocrinology - Diabetes - Fast Facts | NEJM Resident 360</h1><p class=meta>最後更新於
Feb 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Endocrinology%20-%20Diabetes%20-%20Fast%20Facts%20%20NEJM%20Resident%20360.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><p>at: <a href=/inbox rel=noopener class=internal-link data-src=/inbox>inbox</a></p><a href=#endocrinology---diabetes---fast-facts--nejm-resident-360><h1 id=endocrinology---diabetes---fast-facts--nejm-resident-360><span class=hanchor arialabel=Anchor># </span>Endocrinology - Diabetes - Fast Facts | NEJM Resident 360</h1></a><p>Diabetes is a common condition that is managed in both the inpatient and outpatient settings. The two main types of diabetes are type 1 and type 2. Highlighted below are some of the classic characteristics of type 1 and type 2 diabetes. However, these characteristics often overlap, and patients may present with mixed features.</p><a href=#distinguishing-features-of-type-1-and-type-2-diabetes><h3 id=distinguishing-features-of-type-1-and-type-2-diabetes><span class=hanchor arialabel=Anchor># </span>Distinguishing Features of Type 1 and Type 2 Diabetes</h3></a><table><thead><tr><th></th><th>Type 1 Diabetes</th><th>Type 2 Diabetes</th></tr></thead><tbody><tr><td><strong>Etiology</strong></td><td>Autoimmune destruction of pancreatic β-cells</td><td>Insulin resistance with inadequate compensatory β-cell function</td></tr><tr><td><strong>Insulin levels</strong></td><td>Absent or negligible</td><td>Typically, higher than normal</td></tr><tr><td><strong>Insulin action</strong></td><td>Absent or negligible</td><td>Decreased</td></tr><tr><td><strong>Insulin resistance</strong></td><td>Not part of syndrome but may be present (e.g., in patients with obesity)</td><td>Yes</td></tr><tr><td><strong>Age of onset</strong></td><td>Typically &lt;30 years</td><td>Typically, >40 years</td></tr><tr><td><strong>Acute complications</strong></td><td>Ketoacidosis</td><td></td></tr><tr><td>Wasting</td><td>Hyperglycemia (can lead to hyperosmotic seizures and coma)</td><td></td></tr><tr><td><strong>Chronic complications</strong></td><td>Neuropathy</td><td></td></tr><tr><td>Retinopathy</td><td></td><td></td></tr><tr><td>Nephropathy</td><td></td><td></td></tr><tr><td>Peripheral vascular disease</td><td></td><td></td></tr><tr><td>Coronary artery disease</td><td>(Same as type 1)</td><td></td></tr><tr><td><strong>Pharmacologic interventions</strong></td><td>Insulin</td><td>Multiple drug classes are available, including insulin</td></tr></tbody></table><a href=#adapted-from-principles-of-pharmacology-the-pathophysiologic-basis-of-drug-therapy-fourth-edition-philadelphia-wolters-kluwer-2017><h6 id=adapted-from-principles-of-pharmacology-the-pathophysiologic-basis-of-drug-therapy-fourth-edition-philadelphia-wolters-kluwer-2017><span class=hanchor arialabel=Anchor># </span>(Adapted from: Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Fourth edition. Philadelphia: Wolters Kluwer 2017).</h6></a><ul><li><p><strong>Type 1 diabetes</strong> is due to autoimmune beta-cell destruction that leads to insulin deficiency. Patients typically present with symptomatic hyperglycemia (e.g., polyuria, polydipsia, and weight loss) or with DKA. Often antibodies can be detected early in the disease, including islet cell antibodies (ICA, against cytoplasmic proteins in the beta cell), antibodies to glutamic acid decarboxylase (GAD-65), insulin autoantibodies (IAA) or IA-2A (against protein tyrosine phosphatase). These antibodies might help distinguish type 1 from type 2 diabetes in certain circumstances.</p></li><li><p><strong>Type 2 diabetes</strong> is due to insulin resistance and progressive loss of beta-cell insulin secretion. Onset is usually gradual, with milder forms of hyperglycemia, termed prediabetes, eventually leading to symptomatic hyperglycemia.</p></li><li><p><strong>Other causes of diabetes</strong> include:</p></li><li><ul><li><p>monogenic diabetes syndromes (presenting as neonatal diabetes or maturity-onset diabetes of the young [MODY])</p></li><li><p>drug- or chemical-induced diabetes (e.g., steroid-induced diabetes)</p></li><li><p>diabetes due to diseases of the exocrine pancreas (e.g., cystic fibrosis, chronic pancreatitis, post-pancreatectomy)</p></li></ul></li></ul><p>Key concerns in diabetes care include:</p><ul><li><p>screening and diagnosis of prediabetes/diabetes</p></li><li><p>phenotyping (determining the type of diabetes)</p></li><li><p>long-term (outpatient) management of blood-glucose levels and glycated hemoglobin (HbA1c)</p></li><li><p>prevention and management of diabetic complications</p></li><li><p>management of diabetes in hospitalized patients with infection, acute illness, and varying nutritional status</p></li><li><p>management of glycemic emergencies (hypoglycemia, hyperglycemia, diabetic ketoacidosis, and hyperosmolar hyperglycemic nonketotic syndrome)</p></li></ul><a href=#screening-and-diagnosis><h2 id=screening-and-diagnosis><span class=hanchor arialabel=Anchor># </span>Screening and Diagnosis</h2></a><p><strong>Screening:</strong> Given the high prevalence of impaired glucose tolerance (IGT or prediabetes) and type 2 diabetes, an informal assessment of risk factors or validated tools (e.g., CANRISK diabetes risk calculator) should be considered in the screening of asymptomatic adults at risk of developing diabetes.</p><p>The American Diabetes Association (ADA) recommendations for diabetes screening in asymptomatic adults are outlined in the following table:</p><p><strong>(Source: Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. American Diabetes Association. Diabetes Care 2022.)</strong></p><p>*The United States Preventive Services Task Force (USPSTF) recommends screening for prediabetes and type 2 diabetes in all adults aged 35 to 70 years who have overweight or obesity.</p><p><strong>Diagnosis:</strong> Diagnosis of type 2 diabetes requires two abnormal test results from the same blood sample (e.g., abnormal HbA1c and fasting plasma glucose) or in two separate test samples. If the patient presents with a clear clinical picture of hyperglycemia (e.g., polyuria, polydipsia), then a single abnormal test is sufficient to make the diagnosis.</p><p>The following tests can be used to both screen for and diagnose diabetes:</p><ul><li><p>fasting plasma glucose (FPG)</p></li><li><p>2-hour plasma glucose concentration during a 75-g oral glucose tolerance test (OGTT)</p></li><li><p>HbA1c</p></li></ul><p>Thresholds for diagnosis of IGT and type 2 diabetes based on each of these tests are provided in the following table:</p><a href=#thresholds-for-diagnosis-of-igt-and-type-2-diabetes><h3 id=thresholds-for-diagnosis-of-igt-and-type-2-diabetes><span class=hanchor arialabel=Anchor># </span>Thresholds for Diagnosis of IGT and Type 2 Diabetes</h3></a><table><thead><tr><th>Test</th><th>Normal</th><th>IFG or IGT</th><th>Type 2 Diabetes</th></tr></thead><tbody><tr><td>Hemoglobin A1c level, %</td><td>&lt;5.7</td><td>5.7–6.4</td><td>≥6.5</td></tr><tr><td>Fasting plasma glucose level</td><td></td><td></td><td></td></tr><tr><td>mmol/L</td><td></td><td></td><td></td></tr><tr><td>mg/dL</td><td></td><td></td><td></td></tr><tr><td>&lt;5.6</td><td></td><td></td><td></td></tr><tr><td>&lt;100</td><td></td><td></td><td></td></tr><tr><td>5.6–6.9</td><td></td><td></td><td></td></tr><tr><td>100–125</td><td></td><td></td><td></td></tr><tr><td>≥7.0</td><td></td><td></td><td></td></tr><tr><td>≥126</td><td></td><td></td><td></td></tr><tr><td>OGTT results</td><td></td><td></td><td></td></tr><tr><td>mmol/L</td><td></td><td></td><td></td></tr><tr><td>mg/dL</td><td></td><td></td><td></td></tr><tr><td>7.8</td><td></td><td></td><td></td></tr><tr><td>&lt;140</td><td></td><td></td><td></td></tr><tr><td>7.8–11.0</td><td></td><td></td><td></td></tr><tr><td>140–199</td><td></td><td></td><td></td></tr><tr><td>≥11.1</td><td></td><td></td><td></td></tr><tr><td>≥200</td><td></td><td></td><td></td></tr></tbody></table><a href=#abbreviations-igt-impaired-glucose-tolerance-ifg-impaired-fasting-glucose-ogtt-oral-glucose-tolerance-test><h6 id=abbreviations-igt-impaired-glucose-tolerance-ifg-impaired-fasting-glucose-ogtt-oral-glucose-tolerance-test><span class=hanchor arialabel=Anchor># </span>Abbreviations: IGT, impaired glucose tolerance; IFG, impaired fasting glucose; OGTT, oral glucose tolerance test</h6></a><p>(Reference: American Diabetes Association Standards of Medical Care in Diabetes—2022. Diabetes Care 2022.)</p><p><strong>Phenotyping of diabetes:</strong> All patients with new-onset diabetes should be evaluated to determine the type of diabetes. To identify less-common forms of diabetes, the patient should be evaluated for symptoms, medications, family history, and physical examination findings that may suggest genetic or secondary causes of diabetes. Targeted laboratory evaluation can be performed to further evaluate for conditions suspected after this initial clinical assessment.</p><p>Patients who present with features most consistent with type 1 diabetes (e.g., before puberty, with diabetic ketoacidosis, and/or without the typical findings of type 2 diabetes, including obesity or acanthosis nigricans) should be tested for islet autoantibodies. This typically involves measurements of antibodies directed against glutamic acid decarboxylase 65 (GAD65), the 40K fragment of tyrosine phosphatase (IA2), insulin, and/or zinc transporter 8 (ZnT8). Levels of C peptide can also be useful. In older patients with typical features of type 2 diabetes, no additional testing is needed. Autoantibody and C-peptide testing as described above can be helpful in patients with atypical features.</p><a href=#management-of-blood-glucose-in-diabetes><h2 id=management-of-blood-glucose-in-diabetes><span class=hanchor arialabel=Anchor># </span>Management of Blood Glucose in Diabetes</h2></a><p><strong>Blood-glucose testing:</strong> It is helpful for patients with diabetes to regularly engage in blood glucose monitoring (BGM). This is typically done through measurements of capillary blood glucose using lancets and glucometers (fingerstick glucose measurements), although measurement of interstitial fluid glucose levels using continuous glucose monitors (CGMs) is becoming increasing popular both in patients with type 1 and type 2 diabetes.</p><p>All patients with diabetes should check their blood glucose level when they are unwell or feel symptomatic for hyper- or hypoglycemia. Frequency of BGM will depend on the individual patient’s medication regimen (e.g., testing may be omitted altogether in patients who are not taking medications that cause hypoglycemia, while patients requiring insulin may need to test ≥4 times per day).</p><p><strong>Glycated hemoglobin targets:</strong> In patients with diabetes, HbA1c should be tested at least twice annually. In general, the HbA1c target for people with diabetes is &lt;7.0% and ideally around 6.5%. However, goals should be individualized and based on the patient’s age, comorbidities, resources, and risk for hypoglycemia. For example, in an elderly patient with established cardiovascular disease or multiple other comorbidities, the HbA1c target is less stringent (HbA1c of 7.5% to 8.5%) because the risk of harm associated with hypoglycemia outweighs the benefits gained from glycemic control.</p><p>The following figure shows the factors to consider when setting a specific glycemic target:</p><p><strong>Patient and disease factors used to determine optimal glycemic targets. Characteristics and predicaments toward the left justify more stringent efforts to lower A1C; those toward the right suggest less stringent efforts. A1C 7% = 53 mmol/moL.<br>(Source: Glycemic Targets: Standards of Medical Care in Diabetes—2022. American Diabetes Association. Diabetes Care 2022.)</strong></p><a href=#general-glycemic-targets-for-adults-with-diabetes><h3 id=general-glycemic-targets-for-adults-with-diabetes><span class=hanchor arialabel=Anchor># </span>General Glycemic Targets for Adults with Diabetes</h3></a><a href=#management-of-type-1-diabetes><h3 id=management-of-type-1-diabetes><span class=hanchor arialabel=Anchor># </span>Management of Type 1 Diabetes</h3></a><p>Patients with type 1 diabetes have absolute insulin deficiency due to beta-cell destruction. Therefore, all patients with type 1 diabetes require insulin. Omission of insulin places patients with type 1 diabetes at risk of hyperglycemia and diabetic emergencies (e.g., diabetic ketoacidosis).</p><p><strong>Insulin</strong> is usually administered via multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) via an insulin pump. Although insulin regimens vary, the primary principles for insulin administration in patients with type 1 diabetes are:</p><ul><li><p>basal insulin to cover baseline metabolic requirements (long-acting insulin analogue such as insulin glargine or via insulin pump)</p></li><li><p>bolus insulin to cover meal-time carbohydrate intake and prevent postprandial hyperglycemia (short-acting insulin such as insulin aspart)</p></li><li><p>correctional insulin to bring a high blood glucose level down into the target range</p></li><li><p>newer closed-loop systems (“artificial pancreas”) integrate the insulin pump with a continuous glucose monitor (CGM). The system adjusts basal insulin based on real-time glucose levels, but still requires manual entry of prandial insulin doses for meal-time coverage.</p></li></ul><p><strong>Noninsulin pharmacologic treatments</strong> (e.g., metformin and sodium–glucose cotransporter-2 [SGLT-2] inhibitors) have been investigated in many trials as potential adjuncts for treatment in type 1 diabetes. However, these adjuncts are not approved for use in type 1 diabetes at this time.</p><p><strong>Surgery:</strong> Pancreas transplantation or islet cell transplantation are two options for management of type 1 diabetes offered to very select patients and should not be considered part of routine care.</p><a href=#management-of-type-2-diabetes><h3 id=management-of-type-2-diabetes><span class=hanchor arialabel=Anchor># </span>Management of Type 2 Diabetes</h3></a><p>The three main approaches to managing diabetes and blood-glucose levels are:</p><ul><li><p>comprehensive lifestyle management</p></li><li><p>pharmacologic therapy</p></li><li><p>surgery</p></li></ul><p><strong>Lifestyle management:</strong> Lifestyle management is a key component of diabetes management, and all patients diagnosed with diabetes should make lifestyle changes, including the following:</p><ul><li><p>diabetes self-management education and support</p></li><li><p>nutritional/dietary changes</p></li><li><p>increase of physical activity and weight loss (when appropriate)</p></li><li><p>smoking-cessation counseling (when applicable)</p></li><li><p>psychosocial care</p></li></ul><p><strong>Pharmacologic therapy:</strong> Types of pharmacologic treatment for type 2 diabetes include:</p><ul><li><p>oral agents (e.g., metformin, SGLT-2 inhibitors, sulfonylureas, and meglitinides)</p></li><li><p>injectable agents that are not insulin (e.g., glucagon-like peptide-1 [GLP-1] analogues)</p></li><li><p>insulin</p></li></ul><p>As with glycemic targets, choice of pharmacologic agents should be individualized. Metformin is typically recommended as the first-line agent, with more individualization possible when choosing second-line therapies. For example, an overweight 60-year-old man with heart failure will derive greater benefit from an SGLT-2 inhibitor than a sulfonylurea.</p><a href=#comparison-of-pharmacologic-treatments-for-type-2-diabetes><h3 id=comparison-of-pharmacologic-treatments-for-type-2-diabetes><span class=hanchor arialabel=Anchor># </span>Comparison of Pharmacologic Treatments for Type 2 Diabetes</h3></a><p>| Drug | Mechanism<br>of Action | Efficacy  | Hypoglycemia Risk | Effect on Weight | Effect on</p><table><thead><tr><th>CVD Risk</th><th>Comments</th><th></th><th></th><th></th><th></th><th></th></tr></thead><tbody><tr><td><strong>Oral Agents</strong></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Metformin</td><td>Not fully understood, but</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>primarily by</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>reducing hepatic</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>gluconeogenesis</td><td>High</td><td>None</td><td>Neutral or reduction</td><td>Potential benefit for atherosclerotic disease</td><td>GI adverse effects</td><td></td></tr></tbody></table><p>Start at low dose, with gradual up-titration</p><p>Potential B<sub>12</sub> deficiency |
| SGLT-2 inhibitor (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) | Prevents renal<br>tubule glucose<br>reabsorption<br>by inhibiting<br>SGLT-2 activity | Medium | None | Reduction | ↓ CVD risk<br>(atherosclerotic disease and CHF) | Also has renal benefit</p><p>↑ risk of fractures</p><p>↑ risk of DKA</p><p>↑ risk of amputation<br>(canagliflozin only) |
| DPP-4 inhibitor (sitagliptin, linagliptin, saxagliptin, alogliptin, vildagliptin) | Blocks enzyme<br>(DPP-4) that causes<br>breakdown of incretins<br>that stimulate<br>insulin secretion | Medium | None | Neutral | No benefit | ↑ risk of acute pancreatitis |
| Sulfonylurea (glipizide, gliclazide, glyburide, glimepiride) | Increases<br>beta-cell<br>insulin secretion | High | ↑ risk in patients with impaired liver or kidney function | Increase | No benefit | Dose reduction needed in elderly<br>due to hypoglycemia risk |
| Thiazolidinediones (pioglitazone, rosiglitazone) | Bind to peroxisome<br>proliferator-<br>activated receptor<br>gamma in<br>adipocytes</p><p>Promotes<br>adipogenesis and<br>lipid availability | High | None | Increase | Potential ↑ risk of CHF</p><p>Potential benefit for atherosclerotic disease (pioglitazone) | Generally reserved as last-line treatment</p><p>Possible ↑ risk of edema and CHF</p><p>Uncertain benefit in NASH |
| <strong>Injectable Agents</strong> |
| GLP-1 analogues (dulaglutide, exenatide, liraglutide, semaglutide*) | Synthetic incretins<br>that stimulate insulin<br>secretion | High | None | Reduction | Cardiovascular benefit  | Uncertain risk of thyroid C-cell tumor</p><p>GI adverse effects</p><p>Injection-site reactions |
| Insulin analogues | Synthetic insulin | High | ↑ risk in patients with impaired kidney function | Increase | No benefit | |</p><a href=#semaglutide-is-also-available-in-a-once-daily-oral-formulation><h6 id=semaglutide-is-also-available-in-a-once-daily-oral-formulation><span class=hanchor arialabel=Anchor># </span>*Semaglutide is also available in a once-daily oral formulation</h6></a><p>Abbreviations: CVD, cardiovascular disease; GI, gastrointestinal; SGLT-2, sodium–glucose cotransporter-2; CHF, congestive heart failure; DKA, diabetic ketoacidosis; DPP-4, dipeptidyl peptidase 4; NASH, nonalcoholic steatohepatitis; GLP-1, glucagon-like peptide-1<br>(Reference: Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. American Diabetes Association. Diabetes Care 2022.)</p><a href=#glucose-lowering-medication-in-type-2-diabetes><h3 id=glucose-lowering-medication-in-type-2-diabetes><span class=hanchor arialabel=Anchor># </span>Glucose-Lowering Medication in Type 2 Diabetes</h3></a><p><strong>(Source: American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. American Diabetes Association Diabetes Care 2022.)</strong></p><p><strong>Surgery:</strong> Metabolic surgery is a potential treatment option in patients with type 2 diabetes and BMI ≥40 kg/m<sup>2</sup> (BMI ≥37.5 in Asian Americans) and in adults with BMI 35.0–39.9 (32.5–37.4 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with reasonable nonsurgical methods. In the appropriate patient, increasing evidence indicates that metabolic surgery is associated with improved cardiovascular outcomes and sustained glycemic control, compared with lifestyle and pharmacologic treatments alone.</p><p>For more information on metabolic surgery, see the Obesity section in this rotation guide.</p><a href=#diabetic-complications><h3 id=diabetic-complications><span class=hanchor arialabel=Anchor># </span>Diabetic Complications</h3></a><p>Diabetic complications can be classified as microvascular and macrovascular disease. Microvascular disease comprises nephropathy, retinopathy, and neuropathy. Macrovascular complications include coronary artery disease, cerebrovascular disease, and peripheral vascular disease.</p><p>Management of patients with diabetes requires regular assessment for potential complications and management of cardiovascular risk factors. Due to the autoimmune nature of type 1 diabetes, additional screening should be performed in this patient group for other autoimmune diseases.</p><a href=#routine-follow-up-in-patients-with-diabetes><h3 id=routine-follow-up-in-patients-with-diabetes><span class=hanchor arialabel=Anchor># </span>Routine Follow-up in Patients with Diabetes</h3></a><table><thead><tr><th>Clinical Concern</th><th>Examination/ Testing</th><th>Target</th><th>Follow-up</th><th>Treatment</th><th>Comments</th></tr></thead><tbody><tr><td>Hypertension</td><td>Measure BP</td><td>≤120/80 mm Hg</td><td>Every clinic visit</td><td>First-line: ACE inhibitors or ARBs due to renoprotective effects</td><td>Consider 24h BP monitoring</td></tr><tr><td>Overweight/Obesity</td><td>Measure weight and height</td><td>BMI:</td><td></td><td></td><td></td></tr><tr><td>18.5–24.9 kg/m<sup>2</sup></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(lower for Asians)</td><td>Every clinic visit</td><td>Target: achieve and maintain</td><td></td><td></td><td></td></tr></tbody></table><blockquote><p>5% weight loss</p></blockquote><p>Encourage balanced diet and regular physical activity</p><p>Pharmacotherapy and metabolic surgery for certain patients | High-intensity diet, physical and behavioral therapy (>16 sessions in 6 months) aimed to achieve 500–750 kcal/day energy deficit |
| Dyslipidemia | Fasting lipids | LDL cholesterol &lt;100 mg/dL (2.6 mmol/L) OR &lt;70 mg/dL if high cardiac risk</p><p>Triglycerides<br>&lt;150 mg/dL<br>HDL >40 mg/dL | At least every 5 years (if no statin therapy)</p><p>Annually, if treated | Patients aged &lt;40 years: Commence statin treatment based on previous ASCVD event </p><p>Patients aged >40 years: Start primary prevention with moderate-intensity statin for lower ASCVD risk and high-intensity statin for higher risk</p><p>Triglyceride-lowering agents (e.g., icosapent ethyl) can be considered in<br>high-risk patients with triglyceride levels ≥150 mg/dL) | In patients aged >75 years with no history of cardiac event, consider risk-benefit profile of statin therapy |
| Lipohypertrophy | Skin exam | No lipohypertrophy | Every clinic visit | Avoid insulin injection into sites of lipohypertrophy | |
| Peripheral neuropathy | Comprehensive foot exam | Maintain overall foot health | Annually | Adequate glycemic control</p><p>Regular podiatry review if neuropathy present | Foot exam: inspection, pedal pulses, and sensation (pin prick, vibration, 10-g monofilament) |
| Retinopathy | Fundal exam | Maintain vision | Annually | Adequate glycemic control</p><p>Consider fibrates with comorbid dyslipidemia | |
| Nephropathy | UACR</p><p>eGFR | &lt;30 mg/gCr<br>Moderately increased albuminuria (microalbuminuria)<br>UACR: 30–299 mg/gCr</p><p>Severely increased albuminuria (macroalbuminuria)<br>UACR >300 mg/gCr</p><blockquote><p>90 mL/min/<br>1.73 m<sup>2</sup> | At least annually | Adequate glycemic control</p></blockquote><p>Control blood pressure (ACE inhibitor or ARB)</p><p>Consider adjunct of SGLT-2 inhibitor in type 2 diabetes | UACR can be falsely elevated within 24 hours of exercise and with fever, infection, CHF, menstruation, and marked hypertension |
| Nonalcoholic steatohepatitis | Liver-function tests</p><p>Hepatic transaminases | Within normal range | At least annually | Weight loss<br>Glycemic control | Consider further investigation with liver ultrasound |
| <strong>Type 1 Diabetes Only</strong> |
| Other autoimmune disease | Celiac serology</p><p>Thyroid function</p><p>| Negative</p><p>Within normal range | Ask about symptoms annually</p><p>Test at diagnosis and then  periodically thereafter | Treat individual autoimmune condition | No specific guidelines on frequency of screening |</p><a href=#abbreviations-bp-blood-pressure-ace-angiotensin-convertingenzyme-arbs-angiotensin-iireceptor-blockers-ascvd-arteriosclerotic-cardiovascular-disease-uarc-urine-albumin-to-creatinine-ratio-uacr-egfr-estimated-glomerular-filtration-rate><h6 id=abbreviations-bp-blood-pressure-ace-angiotensin-convertingenzyme-arbs-angiotensin-iireceptor-blockers-ascvd-arteriosclerotic-cardiovascular-disease-uarc-urine-albumin-to-creatinine-ratio-uacr-egfr-estimated-glomerular-filtration-rate><span class=hanchor arialabel=Anchor># </span>Abbreviations: BP, blood pressure; ACE, angiotensin-converting–enzyme; ARBs, angiotensin II–receptor blockers; ASCVD, arteriosclerotic cardiovascular disease; UARC, urine albumin-to-creatinine ratio (UACR); eGFR, estimated glomerular filtration rate</h6></a><a href=#hypoglycemia-in-diabetes><h2 id=hypoglycemia-in-diabetes><span class=hanchor arialabel=Anchor># </span>Hypoglycemia in Diabetes</h2></a><p>Hypoglycemia is defined as blood-glucose concentration below 72 mg/dL. However, some patients experience symptoms before blood-glucose concentrations are so low. Symptoms can be classified as adrenergic (autonomic; e.g., sweating, shaking, palpitations) or neuroglycopenic (due to alterations in brain function; e.g., hunger, difficulty concentrating, confusion).</p><a href=#common-precipitating-factors><h3 id=common-precipitating-factors><span class=hanchor arialabel=Anchor># </span>Common Precipitating Factors</h3></a><p>Hypoglycemia can be caused by:</p><ul><li><p>incorrect insulin or long-acting sulfonylurea administration</p></li><li><p>variation in carbohydrate intake</p></li><li><p>suppression of glucose production in the liver by alcohol</p></li><li><p>vigorous or prolonged exercise</p></li><li><p>intercurrent illness</p></li></ul><p><strong>Hypoglycemic unawareness</strong> occurs when patients no longer experience adrenergic symptoms but directly experience neuroglycopenic symptoms. Usually, neuroglycopenic symptoms occur at a lower blood-glucose concentration. Patients with hypoglycemic unawareness are at risk of more-severe complications. Hypoglycemic unawareness can potentially be corrected by strict avoidance of hypoglycemia for 2 to 3 months.</p><a href=#treatment><h3 id=treatment><span class=hanchor arialabel=Anchor># </span>Treatment</h3></a><ul><li><p>Nonsevere hypoglycemia (patient is conscious and capable of self-management) can be treated with fast-acting oral glucose (15 g) such as fruit juice or glucose gel.</p></li><li><p>Severe hypoglycemia (patient is unconscious or unable to perform self-management) needs to be treated with intramuscular or nasal glucagon and potentially intravenous glucagon.</p></li><li><p>All patients should be encouraged to consume sources of long-acting carbohydrates when able and acute hypoglycemia has been corrected.</p></li></ul><p><a href=/inbox rel=noopener class=internal-link data-src=/inbox>inbox</a></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/all-list-of-resident360/ data-ctx="Endocrinology - Diabetes - Fast Facts  NEJM Resident 360" data-src=/all-list-of-resident360 class=internal-link>all list of resident360</a></li><li><a href=/endocrinology/ data-ctx="Endocrinology - Diabetes - Fast Facts  NEJM Resident 360" data-src=/endocrinology class=internal-link>endocrinology</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>